Quick Answer
Protara Therapeutics, Inc. reported Cash and Equivalents of $49.66 million for fiscal year 2025.
Protara Therapeutics, Inc. Cash and Equivalents — Annual History
| Fiscal Year | Cash and Equivalents | YoY Change |
|---|---|---|
| 2025 | $49.66M | -69.5% |
| 2024 | $162.80M | +311.3% |
| 2023 | $39.59M | +64.1% |
| 2022 | $24.13M | -32.5% |
| 2021 | $35.72M | -78.8% |
| 2020 | $168.60M | +29793.3% |
| 2019 | $564.0K | -97.1% |
| 2018 | $19.37M | -8.5% |
| 2017 | $21.17M | -41.8% |
| 2016 | $36.39M | -9.1% |
| 2015 | $40.03M | -41.8% |
| 2014 | $68.84M | +2364.7% |
| 2013 | $2.79M | +15.9% |
| 2012 | $2.41M | -26.3% |
| 2011 | $3.27M | — |
Quarterly Cash and Equivalents
| Quarter Ending | Cash and Equivalents | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $12.55M | -75.8% | -60.2% |
| June 30, 2025 | $31.50M | -64.8% | -65.6% |
| March 31, 2025 | $91.46M | +75.1% | -43.8% |
| December 31, 2024 | $162.80M | +311.3% | +214.5% |
| September 30, 2024 | $51.76M | +53.3% | -42.2% |
| June 30, 2024 | $89.58M | +163.6% | +71.5% |
| March 31, 2024 | $52.23M | +148.3% | +31.9% |
| December 31, 2023 | $39.59M | +64.1% | +17.2% |
- Protara Therapeutics, Inc. showed a decrease of -69.5% in Cash and Equivalents compared to the prior fiscal year.
- Over the 2011–2025 period, Protara Therapeutics, Inc.’s cash and equivalents has grown by 1418.6% (from $3.27 million to $49.66 million).
- The most recent figure is from Protara Therapeutics, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 10, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: